All Life Sciences & Technology News
Top stories summarized by our editors
10/22/2019

Pfizer is the sole US manufacturer of pediatric cancer drug vincristine since Teva discontinued production, and treatment centers such as Texas Children's Hospital and the MD Anderson Cancer Center are concerned that available doses may need to be rationed. Vincristine deliveries are scheduled to resume by late October, but the shortage may last into December, according to the FDA.

10/22/2019

The Bakken Museum recently allowed Medical Design & Outsourcing into the backroom for a private tour. Here are nine items we found there, designed to cure what ails us. They should pique your curiosity -- and maybe raise the hair on the back of your neck. Read this story.

10/22/2019

The Arizona Health Care Cost Containment System said the state will be postponing the implementation of its Medicaid work requirements "as court cases in other states play out, to avoid disruptions to and protect Arizona's most vulnerable members." Arizona received approval from the Trump administration to implement the changes as soon as Jan. 1, 2020.

Full Story:
The Associated Press
More Summaries:
Trump
10/22/2019

United Therapeutics announced the FDA has approved its supplemental new drug application for Orenitram, or treprostinil, seeking updated labeling for the extended-release tablets to include data from its FREEDOM-EV trial in patients with pulmonary arterial hypertension.

Full Story:
Seeking Alpha
10/22/2019

At the October meeting of the European Medicines Agency's Committee for Medicinal Products for Human Use, the regulators issued positive opinions for seven medications, which included Ervebo, or rVSVΔG-ZEBOV-GP, the first vaccine for Ebola. Other drugs backed for approval were Baqsimi for severe hypoglycemia, Quofenix to treat acute bacterial skin infections in adults, Rinvoq for rheumatoid arthritis, Spravato for major depressive disorders in adults that are resistant to treatment, the biosimilar Pegfilgrastim Mundipharma to reduce neutropenia duration and Evenity for severe osteoporosis in postmenopausal women.

10/22/2019

As part of its $21.4 billion plan to acquire GE Life Sciences' biopharma business, Danaher announced it will sell three of its business dealing with life sciences tools to Sartorius Stedim Biotech in a deal worth an estimated $750 million in cash.

More Summaries:
Sartorius Stedim Biotech
10/22/2019

Two travel vaccines developed by GlaxoSmithKline -- Rabipur, an anti-rabies treatment, and Encepur, to prevent tick-borne encephalitis -- will be purchased by Bavarian Nordic of Denmark. Bavarian Nordic will receive $335.71 million as an upfront payment and will be eligible for potential milestone payments.

Full Story:
Reuters
10/22/2019

A partnership forged between British and US universities and charities, including Cancer Research UK, plans to improve current early cancer detection strategies to boost survival rates globally. Although there are screening programs already established for some cancers, there are still a large number of diseases with no screening methods that have very few options for early detection.

Full Story:
PMLive (UK)
10/22/2019

A biotech variety of corn that is highly resistant to a major corn pest called lepidoptera insects and ammonium glufosinate-based herbicides has been authorized by the Colombian Agricultural Institute for planting. The biotech corn was developed in Colombia and will produce higher crop yields compared to conventional seeds.

10/22/2019

New Horizon Health and Prenetics have agreed to a collaboration to market New Horizon's ColoClear colorectal cancer test in Hong Kong and other Asian markets. The test is designed to detect colon cancer in people of Asian descent, and has demonstrated 92% sensitivity in clinical studies.

More Summaries:
Prenetics